-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Figure 1 Keyword frequency analysis of medical and health topics in the two sessions
The importance of the keyword
Figure 2 Analysis of the direction and current situation of the three-medicine linkage reform
For pharmaceutical companies, the three-medicine linkage reform has made the previously less important competitive variables-product, quality, cost, brand, etc.
, become extremely important, while the previously important competitive variable-innovation, will become more important and innovative.
Thresholds and requirements have been more clearly guided
.
This is the best era, and this is also an era of general anxiety
.
We have no way of studying how many people's barbs touched by the hot topics of the two sessions, and how many people's hearts have been comforted
.
We are fortunate to observe the torrent of the times rolling forward, a history of modern medical struggle "Take a stone to leave a mark, grasp the iron to make a mark";
We are fortunate to have witnessed the transition from "lack of medicines and lack of medicines" to starting from generic drugs and becoming a big country of generic drugs and innovative drugs;
We are fortunate that, as a builder, with the continuous deepening of drug management reform, the continuous optimization of the innovation ecology and the fierce competition, it has promoted the transformation and upgrading of China's pharmaceutical industry and reborn itself;
We are fortunate to have experienced the dream of becoming a powerful country in Chinese medicine
.
In the period of pain, how should the medical professionals who are more or less encumbered by the torrent of the times cope? Do you follow the trend? Still survive adversity? Is it a bloody road in the field of strengths? Or is it to start anew in the new era of development hotspots? Is it a real understanding of the country's policy intentions? Or hide the ears and steal the bells to try to make a living? Is it to let go of complaining and move on? Still full of complaints and hard to the end?
But no matter what, "May the world be safe" is not only the initial aspiration of the pharmaceutical company, but also the mission entrusted by the times
.
Those who live up to the people will not be let down by the times .
This must be the best explanation for "adhering to the public welfare of basic medical and health services
.
"
I hope that my colleagues in the pharmaceutical industry will reshape themselves, accumulate more accumulation, move towards excellence, leapfrog development, dance with the times and walk with the people
.
About the Author:
Luo Zhibo, Ph.
D.
, graduated from Tsinghua University.
He is currently the chief engineer of the Pharmaceutical Research Institute of Guangzhou Baiyunshan Pharmaceutical Group Co.
, Ltd.
Baiyunshan General Pharmaceutical Factory.
He is mainly engaged in new drug project evaluation and new drug development
.
As the person in charge, he has completed more than 40 new drug project investigations, participated in the introduction of 8 first-class new drug projects, and has successfully introduced 3 projects
.
Presided over the Guangzhou patent work special fund project, as the main research backbone, participated in the national key research and development plan special project, the major consulting project of the Chinese Academy of Engineering, the National Natural Science Foundation project, the Guangdong Province soft science project and other 6 national, provincial and ministerial projects
.
As the first author, he published 8 SCI papers, 2 Chinese scientific papers, 9 conference papers, applied for 13 patents (3 authorized), and participated in the compilation of 2 monographs
.